These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2475690)

  • 41. Favourable interaction of calcium antagonist plus ACE inhibitor on cardiac haemodynamics in treating hypertension: rest and effort evaluation.
    Di Somma S; Carotenuto A; de Divitiis M; Paulucci A; Galderisi M; Cuocolo A; de Divitiis O
    J Hum Hypertens; 1995 Mar; 9(3):163-8. PubMed ID: 7783096
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics of conventional and slow-release verapamil.
    Follath F; Ha HR; Schütz E; Bühler F
    Br J Clin Pharmacol; 1986; 21 Suppl 2(Suppl 2):149S-153S. PubMed ID: 3756058
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chrono: a community-based hypertension trial of a chronotherapeutic formulation of verapamil.
    Prisant LM; Black HR; Messerli F; Weber M
    Am J Ther; 2002; 9(6):476-83. PubMed ID: 12424503
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term safety and efficacy comparison of immediate-release and sustained-release oral verapamil in systemic hypertension.
    Frishman WH; Eisen G; Charlap S; Strom JA
    J Clin Hypertens; 1987 Dec; 3(4):605-9. PubMed ID: 3134517
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Controlled study on the treatment of hypertension with verapamil in retard form].
    Belz GG; Spies G
    Z Kardiol; 1985 Aug; 74(8):453-9. PubMed ID: 3901562
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Verapamil and prazosin in essential hypertension: evidence of a synergistic combination?
    Elliott HL; Meredith PA; Reid JL
    J Cardiovasc Pharmacol; 1987; 10 Suppl 10():S108-10. PubMed ID: 2455106
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Trough-to-peak ratio and circadian blood pressure profile after treatment with once-daily extended-release diltiazem, 240 mg, in patients with mild-to-moderate essential hypertension.
    Coca A; Sobrino J; Soler J; Módol J; Palos MA; Mínguez A; Esqúe J; Plana J; Cases M; Closas J; de la Sierra A
    J Cardiovasc Pharmacol; 1997 Mar; 29(3):316-22. PubMed ID: 9125668
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Conversion from sustained-release to immediate-release calcium entry blockers: outcome in patients with mild-to-moderate hypertension.
    Hilleman DE; Mohiuddin SM; Lucas BD; Shinn B; Elsasser GN
    Clin Ther; 1993; 15(6):1002-10. PubMed ID: 8111798
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
    Pepine CJ; Handberg EM; Cooper-DeHoff RM; Marks RG; Kowey P; Messerli FH; Mancia G; Cangiano JL; Garcia-Barreto D; Keltai M; Erdine S; Bristol HA; Kolb HR; Bakris GL; Cohen JD; Parmley WW;
    JAMA; 2003 Dec; 290(21):2805-16. PubMed ID: 14657064
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinic blood pressure responses to two amlodipine salt formulations, adipate and besylate, in adult Korean patients with mild to moderate hypertension: a multicenter, randomized, double-blind, parallel-group, 8-week comparison.
    Lee HY; Kang HJ; Koo BK; Oh BH; Heung-Sun K; Kim KS; Seo HS; Ro YM; Kang JH; Woong CJ; Joo SJ; Kim MH; Joon-Han S; Yoon J; Park SH; Jin-Ok J; Ju AK; Chong-Yun R; Yeon KJ; Park KM; Lim DK; Park SY;
    Clin Ther; 2005 Jun; 27(6):728-39. PubMed ID: 16117979
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Casual versus 24-hour ambulatory blood pressure recording in the evaluation of chronic administration of sustained-release verapamil.
    Cardillo C; Savi L; Musumeci V; Mores N; Mettimano M; Costalunga A; Guerrera G; Melina D; Folli G
    J Hum Hypertens; 1988 Mar; 1(4):281-5. PubMed ID: 3221375
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Studies on verapamil in the treatment of essential hypertension: a review.
    Midtbø K; Hals O; Lauve O; van der Meer J; Storstein L
    Br J Clin Pharmacol; 1986; 21 Suppl 2(Suppl 2):165S-171S. PubMed ID: 3530299
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hypertension in the elderly: 24 h ambulatory blood pressure results from a placebo-controlled trial.
    Neutel JM; Smith DH; Lefkowitz MP; Cargo P; Alemayehu D; Weber MA
    J Hum Hypertens; 1995 Sep; 9(9):723-7. PubMed ID: 8551485
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serum concentration and antihypertensive effect of slow-release verapamil.
    Schütz E; Ha HR; Bühler FR; Follath F
    J Cardiovasc Pharmacol; 1982; 4 Suppl 3():S346-9. PubMed ID: 6184566
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).
    Palma Gámiz JL; Pêgo M; Contreras EM; Anglada MP; Martínez JO; Esquerra EA; Sagastagoitia Gorostiza JD;
    Clin Ther; 2006 Dec; 28(12):2040-51. PubMed ID: 17296460
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of amlodipine and verapamil in the treatment of mild to moderate hypertension.
    Lorimer AR; Smedsrud T; Walker P; Tyler HM
    J Cardiovasc Pharmacol; 1988; 12 Suppl 7():S89-93. PubMed ID: 2467138
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sustained-release verapamil: multiple-dose pharmacokinetic comparison of 120-mg and 240-mg tablets and the effect of halving a 240-mg tablet.
    McEwen J; Durnin C; McMurdo ME; Moreland TA
    J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S57-9. PubMed ID: 2475689
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of verapamil and trandolapril in the treatment of hypertension. Trandolapril Study Group.
    Messerli F; Frishman WH; Elliott WJ
    Am J Hypertens; 1998 Mar; 11(3 Pt 1):322-7. PubMed ID: 9544873
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A comparative trial of controlled-onset, extended-release verapamil, enalapril, and losartan on blood pressure and heart rate changes.
    Bakris G; Sica D; Ram V; Fagan T; Vaitkus PT; Anders RJ
    Am J Hypertens; 2002 Jan; 15(1 Pt 1):53-7. PubMed ID: 11824861
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Systolic blood pressure response in three subgroups of hypertensives treated with sustained-release diltiazem.
    Stallard MP; Park GD; Stewart WH; Waller ES; Covinsky JO
    J Cardiovasc Pharmacol; 1988; 12 Suppl 6():S117-9. PubMed ID: 2468893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.